Results 181 to 190 of about 6,312,461 (358)

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

Molecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande, Marcela de Oliveira Silva, Mariana Bisarro dos Reis, Rodrigo de Oliveira Cavagna, Luciane Sussuchi, Icaro Alves Pinto, Natalia Zampieri Pontes, Rodrigo Sampaio Chiarantano, Flavio Augusto Ferreira da Silva, Pedro de Marchi, Letícia Ferro Leal, Rui M. Reis   +11 more
wiley   +1 more source

PB2334: BURDEN OF HOSPITALIZATION, COSTS AND CO-MORBIDITIES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: ANALYSIS OF NATIONAL IN-PATIENT HOSPITAL DATABASE

HemaSphere, 2022
S. Aggarwal, S. Kumar, A. Bela, O. Topaloglu   +3 more
doaj   +1 more source

Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis [PDF]

, 2017
Hadar Goldvaser, T. Barnes, Boštjan Šeruga, David W. Cescon, Alberto Ocaña, Domen Ribnikar, Eitan Amir   +6 more
openalex   +1 more source

How to do a systematic review [PDF]

, 2018
Alex Pollock, Banks JL, Barnett-Page E, Barnett-Page E, Bastian H, Berge E, Bobath B, Boers M, Boger EJ, Booth A, Booth A, Borah R, Brazzelli M, Cahill LS, Carr JH, Chalmers I, Chalmers I, Craig P, Davies PM, Deeks JJ, Dixon-Woods M, Eivind Berge, Fain JA, Feigin VL, Ganann R, Garner P, Glasziou P, Gotzsche PC, Gough D, Gough D, Gough D, Green BN, Greenwood N, Grimshaw J, Guyatt GH, Guyatt GH, Harden A, Higgins JPT, Hoffmann TC, Hoffmann TC, Joanna Briggs Institute, Kastner M, Katrak P, Kirkham JJ, Kreis J, Langhorne P, Lees R, Levac D, Moher D, Moher D, Moher D, Morley RF, Pendlebury ST, Peoples H, PLoS Medicine Editors, Pollock A, Pollock A, Pollock A, Pollock A, Rathbone J, Riva JJ, Rowat A, Sackett DL, Santisteban L, Saunders DH, Silagy CA, Snilstveit B, Stroke Unit Trialists Collaboration, Stroup DF, Thomas J, Tong A, Tyson SF, Tyson SF, Vickrey BG, Waddington H, Wardlaw JM, Weir MC, Whiting PF, Wildridge V, Williamson PR, Wong G, Yaffe J   +81 more
core   +1 more source

A Systematic Review but Systematically Confounded? [PDF]

Journal of Thoracic Oncology, 2010
openaire   +2 more sources

Aggressive prostate cancer is associated with pericyte dysfunction

Molecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero, Ane Martinez‐Larrinaga, Joaquim Grego‐Bessa, Saioa Garcia‐Longarte, Hielke van Splunder, Ianire Astobiza, Amaia Ercilla, Laura Bozal‐Basterra, Isabel Mendizabal, Pilar Villacampa, Arkaitz Carracedo, Mariona Graupera   +11 more
wiley   +1 more source

Head circumference and brain size in autism spectrum disorder: A systematic review and meta-analysis

, 2015
Roberto Sacco, Stefano Gabriele, Antonio M. Persico   +2 more
openalex   +2 more sources

Reviewing the meaning of ‘systematic review’ [PDF]

Australian and New Zealand Journal of Public Health, 2007
Daly, Jeanne., Lumley, Judith Mary.
openaire   +2 more sources

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source

Plasma extrachromosomal circular DNA as a biomarker in EGFR‐targeted therapy of non‐small cell lung cancer

Molecular Oncology, EarlyView.
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard, Sarmad Mehmood, Eva Boysen Fynboe Ebert, Peter Meldgaard, Anindya Dutta, Boe S. Sorensen   +5 more
wiley   +1 more source